Pure Global AI
NCT06061952Not yet recruiting

CAE for Poorly Adherent Individuals With Schizophrenia

Prospective 12-week Randomized Controlled Trial (RCT) of Remotely- Delivered Customized Adherence Enhancement for Poorly Adherent Individuals With Schizophrenia (CAE-S) vs Enhanced Treatment as Usual (eTAU)
Martha SajatovicClinicalTrials.govbehavioral
Verified
Study focus
Disease/Condition
Schizophrenia
Drug/Device/Intervention
Customized Adherence Enhancement for Schizophrenia (CAE-S)
Study type
Interventional
Intervention type
behavioral
Sponsor & location
Primary sponsor
Martha Sajatovic
Funder
University Hospitals Cleveland Medical Center
Location
Cleveland, United States of America
Timeline & enrollment
Phase
N/A
Start date
Dec 15, 2023
End date
Apr 30, 2025
Enrollment
36 participants
Primary outcome

Average number of CAE sessions attended by those in the CAE group after 12 weeks,Percentage of subjects in the CAE group that agree or strongly agree that the intervention was useful at 12 weeks

Summary

This project aims to evaluate the feasibility, acceptability and preliminary efficacy of
 remotely delivered CAE among patients with schizophrenia (CAE-S).

ICD-10 classifications
SchizophreniaSimple schizophreniaSchizophrenia, unspecifiedOther schizophreniaParanoid schizophrenia
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06061952
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06061952 through Pure Global AI's free database. This phase not specified trial is sponsored by Martha Sajatovic and is currently Not yet recruiting. The study focuses on Schizophrenia. Target enrollment is 36 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.